As the global pharmaceutical landscape undergoes a profound transformation, the American Association of Pharmaceutical Scientists (AAPS) is set to host its annual flagship event, PharmSci 360, in New Orleans. Taking place from October 25–28 at the Ernest N. Morial Convention Center, the conference serves as a critical nexus for thousands of industry leaders, academic researchers, and regulatory experts.
The event is designed to cover the entire pharmaceutical product lifecycle, from early-stage discovery and preclinical modeling to clinical translation and regulatory compliance. With a heavy emphasis on "science-first" programming, this year’s summit aims to address the most pressing bottlenecks currently stifling drug development speed, while exploring the next frontier of biological and technological innovation.
The Core Mission: A Science-First Approach to Modern Challenges
The pharmaceutical industry is currently grappling with a dual mandate: the need for unprecedented speed in getting life-saving therapies to market and the increasing complexity of regulatory requirements. AAPS PharmSci 360 provides a forum where these two goals are not viewed as contradictory but as symbiotic elements of a robust development pipeline.
Key organizations participating in this year’s assembly—ranging from heavyweights like AstraZeneca, Merck, and Eli Lilly to specialized research groups like the Mayo Clinic and the University College London—are bringing their latest research to the table. The conference is structured to allow for granular discussions on technology, such as the implementation of New Approach Methodologies (NAMs), organ-on-a-chip models, and advanced pharmacokinetic/pharmacodynamic (PBPK) modeling.
A Detailed Chronology of the Summit
The four-day event is packed with high-level sessions, interactive workshops, and strategic plenaries. Below is the curated trajectory of the event’s most significant highlights.
Sunday, October 25: Setting the Stage
The event kicks off with a keynote address by Dr. Julie Gerberding, President and CEO of the Foundation for the National Institutes of Health (FNIH). Her opening remarks are expected to bridge the gap between bench science and public health impact, framing the conference within the context of global health priorities.
Monday, October 26: Navigating Development Hurdles
Monday focuses heavily on the operational and technical realities of drug development:
- The Executive Autopsy: A standout session, "What Actually Drives Development Speed?", features a multidisciplinary panel including Dr. Leigh Verbois (Rx-360) and Dr. Teresa R. Henry (Blue Oaks Biotech). They will analyze the "why" behind development delays, offering an executive-level post-mortem on project stalling.
- Regulatory Readiness: Dr. Nagendra Chemuturi (Eli Lilly) will lead a critical session on designing biodistribution and persistence strategies compliant with ICH S12 guidelines.
- Biological Complexity: The day concludes with deep dives into hepatocyte models by Dr. Kim L.R. Brouwer and a session on PD-L1 exosomes in oncology by Dr. Mandip Singh Sachdeva, highlighting the role of personalized medicine in cancer research.
Tuesday, October 27: The Era of Advanced Modeling
Tuesday is dominated by the intersection of technology and biology:
- NAMs and Toxicology: Dr. Jeffrey Woodhead (Simulations Plus) will address the advancement of Quantitative Systems Toxicology, a cornerstone for moving away from traditional animal models.
- Clinical Realities: A session on GLP-1-induced gastric emptying, led by Dr. Jessica Atieh of the Mayo Clinic, provides a necessary clinical grounding for current metabolic drug trends.
- Microphysiological Systems: The afternoon features back-to-back sessions on organ-on-a-chip technology, with experts from Xellar Biosystems and Merck discussing vaccine adjuvant evaluation and drug-induced liver injury (DILI) models.
Wednesday, October 28: Future-Proofing the Industry
The final day focuses on long-term policy and the future of the market:
- Pediatric Policy: A "Hot Topic" panel featuring representatives from the U.S. FDA, Health Canada, and the European Paediatric Formulation Initiative will debate the consistency of global standards for pediatric drug data.
- Industry Evolution: The summit concludes with Dr. David Berry (Averin Capital), who will explore the transformative role of venture capital and technology in shifting the pharmaceutical market paradigm.
Supporting Data: The Rise of Innovator-Curated Tracks
A significant addition to the 2026 program is the introduction of two "Innovator-Curated" tracks. These are not merely administrative additions; they represent a fundamental shift in how AAPS is allowing industry leaders to shape the scientific agenda.
- Research Integrity (October 26): Led by Brian Nosek, this track tackles the reproducibility crisis in science. With contributions from the NIH and Northwestern University, this series seeks to establish a new gold standard for data transparency.
- NAMs Advocacy (October 28): Dr. Thomas Hartung of Johns Hopkins University leads this track. As regulators increasingly favor non-animal testing methods, the inclusion of companies like VeriSim Life and 28Bio highlights a pivotal shift toward computational, "in silico" biology.
Official Responses and Collaborative Partnerships
A major headline for the 2026 event is the new, formalized partnership between AAPS and the United States Pharmacopeia (USP). For the first time, USP scientists will maintain a dedicated presence inside the exhibit hall, conducting sessions on excipient quality, inhalation standards, and the nuances of complex generics.
"This collaboration is a direct response to the industry’s need for standardized, clear regulatory pathways," notes an AAPS spokesperson. By moving these discussions out of the lecture halls and into the exhibit floor, the organization is fostering a more "on-demand" learning environment that benefits researchers who need immediate, actionable regulatory intelligence.
Implications: Building the Career of the Future
The implications of PharmSci 360 extend far beyond the data presented on stage. With the "Careers 360" initiative, the conference explicitly acknowledges that the next generation of scientists requires more than just academic knowledge—they need soft skills and career infrastructure.
- AI Skill-Building: As AI/ML becomes a prerequisite in drug discovery, the conference offers dedicated training on integrating these tools into existing workflows.
- Startup Funding: For those in the biotech sector, the focus on IP management and securing funding is designed to provide the necessary "business of science" literacy.
- Networking and Mentorship: By providing resume reviews and access to executive coaches, AAPS is positioning PharmSci 360 as a holistic career ecosystem rather than a passive conference.
The Broader Industry Outlook
The overarching theme of the 2026 summit is "Efficiency through Innovation." Whether it is through the deployment of PBPK modeling, the rigorous application of ICH guidelines, or the adoption of organ-on-a-chip systems, the message is clear: the pharmaceutical industry is no longer satisfied with the status quo.
As the industry converges in New Orleans, the dialogue will move toward the harmonization of global regulatory standards and the ethical adoption of AI. For the scientist, the executive, and the student, PharmSci 360 represents a rare opportunity to see these disparate threads—policy, technology, and career growth—woven into a single, cohesive narrative.
Why Attend?
The complexity of today’s drug development environment necessitates a "community-first" approach. By bringing together the biggest names in the industry—Thermo Fisher, Agilent, 10x Genomics, and IQVIA—alongside the brightest minds in academia and government, AAPS is ensuring that the challenges of 2026 are not faced in isolation.
Attendees are encouraged to register early to secure their spots in the specialized sessions. In an era where the pace of change is accelerating, the knowledge shared in the Ernest N. Morial Convention Center this October will likely define the research priorities for the remainder of the decade.
For more information on the full schedule, speaker biographies, and registration details, visit the official AAPS PharmSci 360 portal.
About the Author
